Foreign-Trade Zone (FTZ) 7-San Juan, Puerto Rico; Notification of Proposed Production Activity; Amgen Manufacturing Limited (Pharmaceuticals), Juncos, Puerto Rico

CourtCommerce Department,Foreign-trade Zones Board
Citation85 FR 26923
Published date06 May 2020
SectionNotices
Record Number2020-09676
Federal Register, Volume 85 Issue 88 (Wednesday, May 6, 2020)
[Federal Register Volume 85, Number 88 (Wednesday, May 6, 2020)]
                [Notices]
                [Pages 26923-26924]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2020-09676]
                =======================================================================
                -----------------------------------------------------------------------
                DEPARTMENT OF COMMERCE
                Foreign-Trade Zones Board
                [B-24-2020]
                Foreign-Trade Zone (FTZ) 7--San Juan, Puerto Rico; Notification
                of Proposed Production Activity; Amgen Manufacturing Limited
                (Pharmaceuticals), Juncos, Puerto Rico
                 Amgen Manufacturing Limited (Amgen) submitted a notification of
                proposed production activity to the FTZ Board for its facility in
                Juncos, Puerto Rico. The notification conforming to the requirements of
                the regulations of the FTZ Board (15 CFR 400.22) was received on April
                28, 2020.
                 Amgen already has authority to produce pharmaceuticals within
                Subzone 7M. The current request would add a foreign status material/
                component to the scope of authority. Pursuant to 15 CFR 400.14(b),
                additional FTZ authority would be limited to the specific foreign-
                status material/component described in the submitted notification (as
                described below) and subsequently authorized by the FTZ Board.
                 Production under FTZ procedures could exempt Amgen from customs
                duty payments on the foreign-status material/component used in export
                production. On its domestic sales, for the foreign-status material/
                component noted below, Amgen would be able to choose the duty rates
                during customs entry procedures that apply to the pharmaceutical
                products in Amgen's existing scope of authority (duty-free). Amgen
                would be able to avoid duty on foreign-status components which become
                scrap/waste. Customs duties also could possibly be deferred or reduced
                on foreign-status production equipment.
                 The material/component sourced from abroad is L-Carnosine (duty
                rate 6.5%). The request indicates that the material/component is
                subject to special duties under Section 301 of the Trade Act of 1974
                (Section 301), depending on the country of origin. The applicable
                Section 301 decisions require subject merchandise to be admitted to
                FTZs in privileged foreign status (19 CFR 146.41).
                 Public comment is invited from interested parties. Submissions
                shall be addressed to the Board's Executive Secretary and sent to:
                [email protected]. The
                [[Page 26924]]
                closing period for their receipt is June 15, 2020.
                 A copy of the notification will be available for public inspection
                in the ``Reading Room'' section of the Board's website, which is
                accessible via www.trade.gov/ftz.
                 For further information, contact Juanita Chen at
                [email protected] or 202-482-1378.
                 Dated: April 30, 2020.
                Andrew McGilvray,
                Executive Secretary.
                [FR Doc. 2020-09676 Filed 5-5-20; 8:45 am]
                 BILLING CODE 3510-DS-P
                

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT